Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

This study tests a personalized cancer vaccine made from your tumor's unique mutations (neoantigens), combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. **You may be eligible if...** - You have an advanced solid tumor with measurable disease - You are willing to provide a fresh tumor biopsy for genetic analysis - If your tumor has a known targetable mutation (e.g., EGFR, ALK, KRAS, BRAF), you must have already tried and progressed on at least one approved targeted therapy - You are able to return to the enrolling institution for follow-up visits **You may NOT be eligible if...** - You have a tumor lesion only in a previously irradiated area (not considered measurable) - You are unable or unwilling to provide tissue samples - You have certain serious health conditions that would prevent you from safely participating Talk to your doctor to see if this trial is right for you.